Determinants of tissue estradiol levels and biologic responsiveness in breast tumors Wei YueSteven J. SantnerRichard J. Santen OriginalPaper Pages: S1 - S7
Molecular analysis of aberrant expression of aromatase in breast cancer tissues Nobuhiro HaradaShin-ichiro Honda OriginalPaper Pages: S15 - S21
Intratumoral aromatase model: The effects of letrozole (CGS 20267) Angela BrodieQing LuYang Liu OriginalPaper Pages: S23 - S26
Clinical importance of intratumoral aromatase W.R. MillerP. MullenJ.M. Dixon OriginalPaper Pages: S27 - S32
Theoretical considerations for the ideal aromatase inhibitor M. Dowsett OriginalPaper Pages: S39 - S44
Pharmacological profiles of exemestane and formestane, steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer Per E. Lønning OriginalPaper Pages: S45 - S52
Pharmacological and clinical profile of anastrozole Per E. LønningJürgen GeislerMitch Dowsett OriginalPaper Pages: S53 - S57
Pre-clinical and clinical review of vorozole, a new third generation aromatase inhibitor Paul E. Goss OriginalPaper Pages: S59 - S65
Fadrozole and letrozole in advanced breast cancer: Clinical and biochemical effects Ian E. SmithAlison Norton OriginalPaper Pages: S67 - S71
Immunolocalization of aromatase in human breast disorders using different antibodies Hironobu SasanoHiroshi Murakami OriginalPaper Pages: S79 - S84
Aromatase expression in the human breast Angela BrodieBrian LongQing Lu OriginalPaper Pages: S85 - S91
Demonstration of aromatase activity and its regulation in breast tumor and benign breast fibroblasts R.J. SantenJ. MartelS. Santner OriginalPaper Pages: S93 - S99
Comparison of biochemical aromatase activity with aromatase immunhistochemistry in human breast carcinomas K.C. ShentonM. DowsettM.G. Rowlands OriginalPaper Pages: S101 - S107
Dr. Richard Santen's editorial changes to discussion following the Friday morning 11 July 1997 session 'Immunochemical approaches to assessing intratumoral aromatase' Legacy Pages: S109 - S120